BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 28555885)

  • 21. Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Jesudian AB; Jacobson IM
    Rev Gastroenterol Disord; 2009; 9(2):E41-7. PubMed ID: 19668124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in pre-liver transplant screening for cholangiocarcinoma among patients with primary sclerosing cholangitis.
    Trilianos P; Selaru F; Li Z; Gurakar A
    Digestion; 2014; 89(2):165-73. PubMed ID: 24577150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
    Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
    J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis.
    Grimsrud MM; Folseraas T
    Liver Int; 2019 Dec; 39(12):2230-2237. PubMed ID: 31216595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis.
    Li L; Masica D; Ishida M; Tomuleasa C; Umegaki S; Kalloo AN; Georgiades C; Singh VK; Khashab M; Amateau S; Li Z; Okolo P; Lennon AM; Saxena P; Geschwind JF; Schlachter T; Hong K; Pawlik TM; Canto M; Law J; Sharaiha R; Weiss CR; Thuluvath P; Goggins M; Shin EJ; Peng H; Kumbhari V; Hutfless S; Zhou L; Mezey E; Meltzer SJ; Karchin R; Selaru FM
    Hepatology; 2014 Sep; 60(3):896-907. PubMed ID: 24497320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.
    Betesh L; Comunale MA; Wang M; Liang H; Hafner J; Karabudak A; Giama NH; Moser CD; Miyoshi E; Roberts LR; Block TM; Mehta A
    Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28561948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary sclerosing cholangitis and cholangiocarcinoma.
    Lazaridis KN; Gores GJ
    Semin Liver Dis; 2006 Feb; 26(1):42-51. PubMed ID: 16496232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: A role for IL-17A.
    Lieshout R; Kamp EJCA; Verstegen MMA; Doukas M; Dinjens WNM; Köten K; IJzermans JNM; Bruno MJ; Peppelenbosch MP; van der Laan LJW; de Vries AC
    Int J Cancer; 2023 Jun; 152(12):2607-2614. PubMed ID: 36346104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma.
    Kerr SE; Barr Fritcher EG; Campion MB; Voss JS; Kipp BR; Halling KC; Lewis JT
    Hum Pathol; 2014 Sep; 45(9):1797-804. PubMed ID: 25027853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma.
    Voigtländer T; Gupta SK; Thum S; Fendrich J; Manns MP; Lankisch TO; Thum T
    PLoS One; 2015; 10(10):e0139305. PubMed ID: 26431155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma.
    Venkatesh PG; Navaneethan U; Shen B; McCullough AJ
    Dig Dis Sci; 2013 Mar; 58(3):850-7. PubMed ID: 23007734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
    Taghavi SA; Eshraghian A; Niknam R; Sivandzadeh GR; Bagheri Lankarani K
    Expert Rev Gastroenterol Hepatol; 2018 Jun; 12(6):575-584. PubMed ID: 29781738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis.
    Quinn KP; Tabibian JH; Lindor KD
    Scand J Gastroenterol; 2017 Apr; 52(4):377-381. PubMed ID: 27908204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNAs and extracellular vesicles in cholangiopathies.
    Olaizola P; Lee-Law PY; Arbelaiz A; Lapitz A; Perugorria MJ; Bujanda L; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1293-1307. PubMed ID: 28711597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.
    Burak K; Angulo P; Pasha TM; Egan K; Petz J; Lindor KD
    Am J Gastroenterol; 2004 Mar; 99(3):523-6. PubMed ID: 15056096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Proteomic analysis of serum and serum exosomes, and their application in intrahepatic cholangiocarcinoma].
    Yang K; Wang W; Wang Y; Yan C
    Se Pu; 2021 Nov; 39(11):1191-1202. PubMed ID: 34677014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2
    Kennedy L; Hargrove L; Demieville J; Karstens W; Jones H; DeMorrow S; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Smith S; Akers A; Meadows V; Francis H
    Hepatology; 2018 Sep; 68(3):1042-1056. PubMed ID: 29601088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms.
    Melum E; Karlsen TH; Schrumpf E; Bergquist A; Thorsby E; Boberg KM; Lie BA
    Hepatology; 2008 Jan; 47(1):90-6. PubMed ID: 18023027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.
    Lankisch TO; Metzger J; Negm AA; Vosskuhl K; Schiffer E; Siwy J; Weismüller TJ; Schneider AS; Thedieck K; Baumeister R; Zürbig P; Weissinger EM; Manns MP; Mischak H; Wedemeyer J
    Hepatology; 2011 Mar; 53(3):875-84. PubMed ID: 21374660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.